

DAFTAR PUSTAKA

1. Rodrigues AM, Beale MA, Hagen F, Fisher MC, Terra PPD, de Hoog S, et al. The global epidemiology of emerging *Histoplasma* species in recent years. *Stud Mycol*. 2020 Sep;97.
2. Guemas E, Sobanska L, Demar M. *Histoplasma capsulatum* and Histoplasmosis: Current Concept for the Diagnosis. In: *Histoplasma and Histoplasmosis*. IntechOpen; 2020.
3. de Perio MA, Benedict K, Williams SL, Niemeier-Walsh C, Green BJ, Coffey C, et al. Occupational Histoplasmosis: Epidemiology and Prevention Measures. *J fungi (Basel, Switzerland)*. 2021 Jun 26;7(7).
4. Yehia MM, Abdulla ZA. Isolation of *Histoplasma capsulatum* and *Blastomyces dermatitidis* from Iraqi patients with lower respiratory tract infections. *J Islam Med Assoc North Am*. 2011 Aug 10;43(2).
5. Tobón AM, Gómez BL. Pulmonary Histoplasmosis. *Mycopathologia*. 2021 Oct;186(5):697–705.
6. Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW, Wright L, et al. Re-drawing the Maps for Endemic Mycoses. *Mycopathologia*. 2020;185(5):843–65.
7. Wijaya M, Adawiyah R, Wahyuningsih R. Histoplasmosis: diagnostic and therapeutic aspect. *Indones J Trop Infect Dis*. 2021;9(2):66.
8. Rozaliyani A, Setianingrum F. The Review of Histoplasmosis Endemicity and Current Status in Asia. *Histoplasma and Histoplasmosis*. 2020;1–15.
9. Azhar T, Mardianto. Prevalensi histoplasmosis pada mahasiswa kedokteran Universitas Islam Sumatera Utara dan hubungan hewan peliharaan dengan tes histoplasmin. *Berkala Ilmu Kedokteran*. 1997;29:139–44.
10. Horwath MC, Fecher RA, Deepe GS. *Histoplasma capsulatum*, lung

- infection and immunity. *Future Microbiol.* 2015 Jun;10(6):967–75.
11. Frías-De León MG. Histoplasmosis: diagnostic challenges. *Case reports.* 2019;5(2):85–8.
 12. Diaz JH. Environmental and Wilderness-Related Risk Factors for Histoplasmosis: More Than Bats in Caves. *Wilderness Environ Med.* 2018 Dec;29(4):531–40.
 13. Araúz AB, Papineni P. Histoplasmosis. *Infect Dis Clin North Am.* 2021;35(2):471–91.
 14. Myint T, Leedy N, Villacorta Cari E, Wheat LJ. HIV-Associated Histoplasmosis: Current Perspectives. *HIV AIDS (Auckl).* 2020;12:113–25.
 15. Rakislova N, Hurtado JC, Palhares AEM, Ferreira L, Freire M, Lacerda M, et al. High prevalence and mortality due to *Histoplasma capsulatum* in the Brazilian Amazon: An autopsy study. Govender NP, editor. *PLoS Negl Trop Dis.* 2021 Apr;15(4).
 16. Miller AC, Arakkal AT, Koeneman SH, Cavanaugh JE, Thompson GR, Baddley JW, et al. Frequency and Duration of, and Risk Factors for, Diagnostic Delays Associated with Histoplasmosis. *J Fungi.* 2022 Apr 23;8(5):438.
 17. Baker J, Kosmidis C, Rozaliyani A, Wahyuningsih R, Denning DW. Chronic Pulmonary Histoplasmosis—A Scoping Literature Review. *Open Forum Infect Dis.* 2020 May 1;7(5).
 18. Marwan M, Azar M, James L, Loyd M, Ryan F, Relich P, L. Joseph Wheat M, Chadi A, Hage M. Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes. *Adv Skin Wound Care.* 2020;33(11):570–80.
 19. Toscanini MA, Nusblat AD, Cuestas ML. Diagnosis of histoplasmosis:

- current status and perspectives. *Appl Microbiol Biotechnol*. 2021 Mar 15;105(5):1837–59.
20. Linder KA, Kauffman CA. Current and new perspectives in the diagnosis of blastomycosis and histoplasmosis. *J Fungi*. 2021;7(1):1–10.
 21. Ocansey BK, Kosmidis C, Agyei M, Dorkenoo AM, Ayanlowo OO, Oladele RO, et al. Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities. *PLoS Negl Trop Dis*. 2022;16(2):1–18.
 22. Lewis PO, Khan I, Patel P. Successful stepdown treatment of pulmonary histoplasmosis with thrice-weekly liposomal amphotericin B in a hospital-associated, outpatient infusion centre: A case report. *J Clin Pharm Ther*. 2018 Apr 14;43(2):269–72.
 23. Abdallah W, Myint T, LaRue R, Minderman M, Gunn S, Wheat LJ, et al. Diagnosis of Histoplasmosis Using the MVista Histoplasma Galactomannan Antigen Qualitative Lateral Flow–Based Immunoassay: A Multicenter Study. *Open Forum Infect Dis*. 2021 Sep 1;8(9).
 24. Hendrix MJ, Larson L, Rauseo AM, Rutjanawech S, Franklin AD, Powderly WG, et al. Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort. *Clin Infect Dis*. 2021;73(11):e3727–32.
 25. Taylor ML, Reyes-Montes MDR, Estrada-Bárcenas DA, Zancopé-Oliveira RM, Rodríguez-Arellanes G, Ramírez JA. Considerations about the Geographic Distribution of *Histoplasma* Species. *Appl Environ Microbiol*. 2022;88(7):e0201021.
 26. Powers-Fletcher M V., Kendall BA, Griffin AT, Hanson KE. Filamentous Fungi. Hayden RT, Wolk DM, Carroll KC, Tang YW, editors. *Microbiol Spectr*. 2016 May;4(3):329–50.
 27. Mruthyunjayappa S LS. *Histoplasma capsulatum* [Internet]. 2022 [cited

- 2022 Jul 5]. Available from: <https://www.pathologyoutlines.com/topic/microbiologyhcapsulatum.html>
28. Limon JJ, Skalski JH, Underhill DM. Commensal Fungi in Health and Disease. *Cell Host Microbe*. 2017 Aug 9;22(2):156–65.
 29. Sil A. Molecular regulation of *Histoplasma* dimorphism. *Curr Opin Microbiol*. 2019;52:151–7.
 30. Jofre GI, Singh A, Mavengere H, Sundar G, D'Agostino E, Chowdhary A, et al. An Indian lineage of *Histoplasma* with strong signatures of differentiation and selection. *Fungal Genet Biol*. 2022 Jan;158:103654.
 31. Akram SM, Koirala J. Histoplasmosis [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28846361>
 32. Shen Q, Rappleye CA. Living Within the Macrophage: Dimorphic Fungal Pathogen Intracellular Metabolism. *Front Cell Infect Microbiol*. 2020;10(October):592259.
 33. Mittal J, Ponce MG, Gendlina I, Nosanchuk JD. *Histoplasma Capsulatum*: Mechanisms for Pathogenesis. *Curr Top Microbiol Immunol*. 2019;422:157–91.
 34. Wheat LJ, Hage CA. Histoplasmosis. *Diagnosis Treat Fungal Infect*. 2015;217–24.
 35. McDermott AJ, Klein BS. Helper T-cell responses and pulmonary fungal infections. *Immunology*. 2018 Oct;155(2):155–63.
 36. Garfoot AL, Shen Q, Wüthrich M, Klein BS, Rappleye CA. The Eng1 β -Glucanase Enhances *Histoplasma* Virulence by Reducing β -Glucan Exposure. Sil A, Berman J, editors. *MBio*. 2016 Apr 19;7(2):e01388-15.
 37. García- Romero MT. Deep Fungal Infections. In: *Harper's Textbook of Pediatric Dermatology*. Wiley; 2019. p. 560–78.
 38. Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, Denning DW.

- Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management. *J Fungi*. 2022 Apr 28;8(5):460.
39. Gnat S, Łagowski D, Nowakiewicz A, Dyląg M. A global view on fungal infections in humans and animals: infections caused by dimorphic fungi and dermatophytoses. *J Appl Microbiol*. 2021 Dec 13;131(6):2688–704.
 40. Semionov A, Rossi A, Perillo M, Sayegh K, Pressacco J, Kosiuk J. Many Faces of Thoracic Histoplasmosis—Pictorial Essay. *Can Assoc Radiol J*. 2019 Aug 1;70(3):273–81.
 41. J. Buitrago M, Valero C. Laboratory Diagnosis of Histoplasmosis: An Update. In: *Histoplasma and Histoplasmosis*. IntechOpen; 2020. p. 131–40.
 42. Alanio A, Gits-Muselli M, Lanternier F, Sturny-Leclère A, Benazra M, Hamane S, et al. Evaluation of a New *Histoplasma* spp. Quantitative RT-PCR Assay. *J Mol Diagnostics*. 2021 Jun;23(6):698–709.
 43. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. *Clin Infect Dis*. 2008;46(12):1813–21.
 44. Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S, Vazquez J, et al. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. *Clin Infect Dis*. 2021 Mar 12;72:S121–7.
 45. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and

- Research Consortium. *Clin Infect Dis*. 2020 Sep 12;71(6):1367–76.
46. Epelboin L, Dione A, Serris A, Blanchet D, Bidaud B, Walter G, et al. Histoplasmosis of the Central Nervous System: A Case Series between 1990 and 2019 in French Guiana. *Am J Trop Med Hyg*. 2021 Jul 7;105(1):125–9.
 47. Falci DiR, Monteiro AA, Braz Caurio CF, Magalhães TCO, Xavier MO, Basso RP, et al. Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection. *Open forum Infect Dis*. 2019 Apr;6(4):ofz073.
 48. Seyedmousavi S. Antifungal Drugs. In: *Burger's Medicinal Chemistry and Drug Discovery*. Wiley; 2021. p. 1–62.
 49. Johnson LR. Respiratory Therapeutics. In: *Canine and Feline Respiratory Medicine*. Wiley; 2020. p. 43–62.
 50. Cherabie J, Mazi P, Rauseo A, Ayres C, Larson L, Rutjanawech S, et al. Long-Term Mortality after Histoplasma Infection in People with HIV. *J Fungi*. 2021 May 8;7(5):369.
 51. Buitrago MJ, Martín-Gómez MT. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. *Front Microbiol*. 2020;11(March):1–8.
 52. Lee PP, Lau YL. Cellular and Molecular Defects Underlying Invasive Fungal Infections-Revelations from Endemic Mycoses. *Front Immunol*. 2017;8(JUN):735.
 53. Zhu C, Wang G, Chen Q, He B, Wang L. Pulmonary histoplasmosis in a immunocompetent patient: A case report and literature review. *Exp Ther Med*. 2016;12(5):3256–60.

54. Sutliff WD, Hughes F, Ulrich E, Burkett LL. Active chronic pulmonary histoplasmosis. *AMA Arch Intern Med.* 1953 Oct 1;92(4):571–86.
55. Sutliff WD, Burkett LL. Chronic Pulmonary Histoplasmosis. *Postgrad Med.* 1956 Aug 18;20(2):125–31.
56. Rubin H, Furcolow ML, Yates JL, Brasher CA. The course and prognosis of histoplasmosis. *Am J Med.* 1959;27(2):278–88.
57. Baum GL, Schwarz J. Chronic pulmonary histoplasmosis. *Am J Med.* 1962;33(6):873–9.
58. Murray JF, Howard D. Histoplasmosis Cooperative Study. II. Chronic Pulmonary Histoplasmosis Treated With and Without Amphotericin B. *Am Rev Respir Dis.* 1964 May;89:641–50.
59. Goodwin RA, Snell JD, Hubbard WW, Terry RT. Early chronic pulmonary histoplasmosis. *Am Rev Respir Dis.* 1966 Jan;93(1):47–61.
60. Goldin AG, Saliba NA. The heart in chronic pulmonary histoplasmosis. *South Med J.* 1967 Jun;60(6):638–42.
61. Newberry WM, Tosh FE, Doto IL, Chin TDY. The complement fixation antibody test in the diagnosis of chronic pulmonary histoplasmosis and blastomycosis. *J Chronic Dis.* 1967;20(5):303–9.
62. Levene N, Slesh MZ, Torres J, Saliba NA. Surgical Aspects of Chronic Progressive Cavitory Pulmonary Histoplasmosis. *Ann Thorac Surg.* 1968;5(1):23–9.
63. Baum GL, Larkin JC, Sutliff WD. Follow-up of patients with chronic pulmonary histoplasmosis treated with amphotericin B. *Chest.* 1970;58(6):562–5.
64. Parker JD, Sarosi GA, Doto IL, Bailey RE, Tosh FE. Treatment of chronic pulmonary histoplasmosis. *N Engl J Med.* 1970 Jul 30;283(5):225–9.
65. Alford RH, Goodwin RA. Patterns of immune response in chronic

- pulmonary histoplasmosis. *J Infect Dis.* 1972;125(3):269–75.
66. Goodwin RA, Owens FT, Snell JD, Hubbard WW, Buchanan RD, Terry RT, et al. Chronic pulmonary histoplasmosis. *Medicine (Baltimore).* 1976 Nov;55(6):413–52.
 67. Smith CR, Griffin DE, Graybill JR. Chronic pulmonary histoplasmosis: improved lymphocyte response with transfer factor. *Ann Intern Med.* 1976 Jun;84(6):708–9.
 68. Straus SE, Jacobson ES. The spectrum of histoplasmosis in a general hospital: a review of 55 cases diagnosed at Barnes Hospital between 1966 and 1977. *Am J Med Sci.* 1980 May;279(3):147–58.
 69. Lowell JR, McLarty JW. Factors relating to recurrence of chronic pulmonary histoplasmosis following treatment with amphotericin B. *Am J Med Sci.* 1983 Jan;285(1):13–23.
 70. Morse DL, Gordon MA, Matte T, Eadie G. An outbreak of histoplasmosis in a prison. *Am J Epidemiol.* 1985;122(2):253–61.
 71. Negroni R, Robles AM, Arechavala A, Taborda A. Itraconazole in human histoplasmosis. *Mycoses.* 1989 Mar;32(3):123–30.
 72. Cobb CM, Shultz RE, Brewer JH, Dunlap CL. Chronic pulmonary histoplasmosis with an oral lesion. *Oral Surgery, Oral Med Oral Pathol.* 1989;67(1):73–6.
 73. McKinsey DS, Kauffman CA, Pappas PG, Cloud GA, Girard WM, Sharkey PK, et al. Fluconazole therapy for histoplasmosis. *Clin Infect Dis.* 1996;23(5):996–1001.
 74. Severo LC, Rizzon CF, Roesch EW, Oliveira F de M, Porto N da S. Chronic pulmonary histoplasmosis in Brazil: report of two cases with cavitation diagnosed by transthoracic needle biopsy. *Rev Inst Med Trop Sao Paulo.* 1997 Sep;39(5):293–7.

75. Capone D, Wanke B, Fialho Monteiro PC, Dos Santos Lazéra M, De Noronha Andrade G, Francesconi Do Valle AC, et al. Chronic pulmonary histoplasmosis in the State of Rio de Janeiro, Brazil. *Mycopathologia*. 1999;145(2):75–9.
76. Pometta R, Trovato C, Conte D, Viviani MA, Masini T. Chronic pulmonary histoplasmosis in a patient with a recent history of tuberculosis and persistent round lung lesions. *Eur J Clin Microbiol Infect Dis*. 1999;18(3):229–31.
77. Kennedy CC, Limper AH. Redefining the clinical spectrum of chronic pulmonary histoplasmosis: A retrospective case series of 46 patients. *Medicine (Baltimore)*. 2007;86(4):252–8.
78. García-Marrón M, García-García JM, Pajín-Collada M, Álvarez-Navascués F, Martínez-Muñiz MA, Sánchez-Antuña AA. Chronic pulmonary histoplasmosis diagnosed in a nonimmunosuppressed patient 10 years after returning from an endemic area. *Arch Bronconeumol*. 2008;44(10):567–70.
79. Ashbee HR, Evans EGV, Viviani MA, Dupont B, Chryssanthou E, Surmont I, et al. Histoplasmosis in Europe: Report on an epidemiological survey from the european confederation of medical mycology working group. *Med Mycol*. 2008;46(1):57–65.
80. Mata-Essayag S, Colella MT, Roselló A, De Capriles CH, Landaeta ME, De Salazar CP, et al. Histoplasmosis: A study of 158 cases in Venezuela, 2000-2005. *Medicine (Baltimore)*. 2008;87(4):193–202.
81. Santos JWA dos, Michel GT, Lazzarotto M, Figaro JK, Spilmann D, Homrich GK. Chronic cavitary pulmonary histoplasmosis. *J Bras Pneumol*. 2009 Nov;35(11):1161–4.
82. Ledtke C, Tomford JW, Jain A, Isada CM, Van Duin D. Clinical presentation and management of histoplasmosis in older adults. *J Am Geriatr Soc*. 2012;60(2):265–70.

83. Faiolla RCL, Coelho MC, Santana R de C, Martinez R. Histoplasmosis in immunocompetent individuals living in an endemic area in the Brazilian Southeast. *Rev Soc Bras Med Trop*. 2013;46(4):461–5.
84. Jung EJ, Park DW, Choi JW, Choi WS. Chronic cavitary pulmonary histoplasmosis in a non-HIV and immunocompromised patient without overseas travel history. *Yonsei Med J*. 2015;56(3):871–4.
85. Kandi V, Vaish R, Palange P, Bhoomagiri MR. Chronic Pulmonary Histoplasmosis and its Clinical Significance: an Under-reported Systemic Fungal Disease. *Cureus*. 2016;8(8).
86. Botsa E, Thanou I, Kabanarou S, Thanos L. Rare case of pulmonary histoplasmosis complicated with bronchocentric granulomatosis in a non endemic area. *Respir Med Case Reports*. 2017;22:1–3.
87. Lee YJ, Kang HR, Song JH, Sin S, Lee SM. Pulmonary histoplasmosis identified by Video-Assisted Thoracic Surgery (VATS) biopsy: A case report. *J Korean Med Sci*. 2018;33(2):1–6.
88. Preneta A, Nada KM, Raja A, Kasubhai M. Chronic Pulmonary Histoplasmosis Identified in a Young Patient with Selective Immunoglobulin M Deficiency. *Case Rep Infect Dis*. 2018;2018:1–4.
89. Geurkink S, Cler L. Spontaneous pneumothorax secondary to chronic cavitary pulmonary histoplasmosis. *J Community Hosp Intern Med Perspect*. 2020;10(5):483–7.
90. Chumpangern W, So-Ngern A, Reechaipichitkul W, Meesing A, Ratanawatkul P, Arunsurat I, et al. Presentations of chronic cavitary pulmonary histoplasmosis mimic infected cystic bronchiectasis in an immunocompetent host: A case report. *Respir Med Case Reports*. 2021;34:101555.
91. Hernández Solís A, Araiza Santibáñez J, Tejeda Olán JG, Quintana Martínez A, Hernández de la Torriente A, de la Torriente Mata R.

- Pulmonary Histoplasmosis in a Referral Hospital in Mexico City. *Can J Infect Dis Med Microbiol.* 2022;2022:1–6.
92. García-Marrón M, García-García JM, Pajín-Collada M, Álvarez-Navascués F, Martínez-Muñiz MA, Sánchez-Antuña AA. Chronic Pulmonary Histoplasmosis Diagnosed in a Nonimmunosuppressed Patient 10 Years After Returning From an Endemic Area. *Arch Bronconeumol* ((English Ed. 2008 Jan;44(10):567–70.
93. Peng Y yin, Guo S liang, Yan X feng, Zhang L lang, Wang J, Yuan G dan, et al. Collective outbreak of severe acute histoplasmosis in immunocompetent Chinese in South America: the clinical characteristics and continuous monitoring of serum cytokines/chemokines. *BMC Prim Care.* 2022 Aug 8;23(1):197.
94. Rahim MA, Zaman S, Amin MR, Uddin KN, Chowdhury MJ. Histoplasmosis: An Emerging or Neglected Disease in Bangladesh? A Systematic Review. *Oman Med J.* 2020 Feb 16;35(1):e91–e91.
95. Berbari HE, Gurram P, Mahmood M, Deziel PJ, Walker RC, Razonable RR. Prosthetic Joint Infections Due to *Histoplasma capsulatum*: A Report of 3 Cases. *Mayo Clin Proc Innov Qual Outcomes.* 2021 Feb;5(1):225–9.
96. Hoyos Pulgarin JA, Alzate Piedrahita JA, Moreno Gómez GA, Sierra Palacio JF, Ordoñez KM, Arias Ramos D. Closing gaps in histoplasmosis: clinical characteristics and factors associated with probable/histoplasmosis in HIV/AIDS hospitalized patients, a retrospective cross-sectional study in two tertiary centers in Pereira, Colombia. *AIDS Res Ther.* 2021;18(1):1–8.
97. Gong Y, Li C, Wang C, Li J, Ding M, Chen D, et al. Epidemiology and Mortality-Associated Factors of Invasive Fungal Disease in Elderly Patients: A 20-Year Retrospective Study from Southern China. *Infect Drug Resist.* 2020 Mar;Volume 13:711–23.
98. Egger M, Hoenigl M, Thompson GR, Carvalho A, Jenks JD. Let's talk

- about sex characteristics—As a risk factor for invasive fungal diseases. *Mycoses*. 2022 Jun 25;65(6):599–612.
99. Bereshchenko O, Bruscoli S, Riccardi C. Glucocorticoids, Sex Hormones, and Immunity. *Front Immunol*. 2018 Jun 12;9(JUN):1–10.
100. Ysraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. *Immunology*. 2019 Jan;156(1):9–22.
101. Thompson GR, Pasqualotto AC. Endemic mycoses: Expansion of traditional geographic ranges and pitfalls in management. *Mycoses*. 2021 Sep 4;64(9):989–92.
102. Brown EM, McTaggart LR, Dunn D, Pszczolko E, Tsui KG, Morris SK, et al. Epidemiology and Geographic Distribution of Blastomycosis, Histoplasmosis, and Coccidioidomycosis, Ontario, Canada, 1990–2015. *Emerg Infect Dis*. 2018 Jul;24(7):1257–66.
103. Roth MT, Zamith-Miranda D, Nosanchuk JD. Immunization Strategies for the Control of Histoplasmosis. *Curr Trop Med Reports*. 2019 Jun 15;6(2):35–41.
104. Peixoto da Silva S, Santos JMO, Costa e Silva MP, Gil da Costa RM, Medeiros R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. *J Cachexia Sarcopenia Muscle*. 2020 Jun 6;11(3):619–35.
105. Pettit AC, Raynor MB, Schwartz HS, Wright PW. Histoplasmosis Masquerading as a Rheumatoid Nodule in an Immunocompromised Host: A Case Report. *JBSJ case Connect*. 2014 Sep 10;4(3):e75.
106. Nemati E, Rahman MM, Nathan V, Vatanparvar K, Kuang J. A Comprehensive Approach for Classification of the Cough Type. In: 2020 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE; 2020. p. 208–12.

107. Meldrum OW, Chotirmall SH. Mucus, Microbiomes and Pulmonary Disease. *Biomedicines*. 2021 Jun 13;9(6):675.
108. Charriot J, Volpato M, Petit A, Vachier I, Bourdin A. Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to “Unplug” from Our Daily Routine! *Cells*. 2022 Feb 25;11(5):812.
109. Nunez D, Rao R, Gray BW, Landman MP. Massive hemoptysis from pulmonary histoplasmosis requiring emergency lung resection and extracorporeal membrane oxygenation. *J Pediatr Surg Case Reports*. 2019;48(June):101260.
110. De La Torre Cruz J, Cañadas Quesada FJ, Ruiz Reyes N, García Galán S, Carabias Orti JJ, Pérez Chica G. Monophonic and Polyphonic Wheezing Classification Based on Constrained Low-Rank Non-Negative Matrix Factorization. *Sensors*. 2021 Feb 28;21(5):1661.
111. De La Torre Cruz J, Cañadas Quesada FJ, Ruiz Reyes N, Vera Candeas P, Carabias Orti JJ. Wheezing Sound Separation Based on Informed Inter-Segment Non-Negative Matrix Partial Co-Factorization. *Sensors*. 2020 May 8;20(9):2679.
112. Hafen BB, Sharma S. Oxygen Saturation [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30247849>
113. Walter JM, Corbridge TC, Singer BD. Invasive Mechanical Ventilation. *South Med J*. 2018;111(12):746–53.
114. Pourahmad J, Aghvami M, Zarei MH, Naserzadeh P. Cigarette Smoke and Mitochondrial Damage. *Mitochondrial Dysfunct Caused by Drugs Environ Toxicants*. 2018;2–2:709–25.
115. Elicker BM, Kallianos KG, Jones KD, Henry TS. Smoking-Related Lung Disease. *Semin Ultrasound, CT MRI*. 2019 Jun;40(3):229–38.
116. Tsai MC, Byun MK, Shin J, Crotty Alexander LE. Effects of e-cigarettes

- and vaping devices on cardiac and pulmonary physiology. *J Physiol*. 2020;598(22):5039–62.
117. Richey BF, Obrock RS, Gee ZM, Lu DY, Jacobsen G, Richards SC. Smoking, Rural Residence and Diabetes as Risk Factors For Presumed Ocular Histoplasmosis Syndrome. *Retina*. 2022 Feb;42(2):369–74.
 118. Liang L, Feng L, Zhou L, Chu S, Zhang D, Jin H, et al. Metabolic Differences between Ex-Smokers and Nonsmokers: A Metabolomic Analysis. *J Healthc Eng*. 2022;2022.
 119. Aloufi N, Namkung Y, Traboulsi H, Wilson ET, Laporte SA, Kaplan BLF, et al. Standardized Cannabis Smoke Extract Induces Inflammation in Human Lung Fibroblasts. *Front Pharmacol*. 2022 Mar 28;13(March):1–13.
 120. Jett J, Stone E, Warren G, Cummings KM. Cannabis Use, Lung Cancer, and Related Issues. *J Thorac Oncol*. 2018;13(4):480–7.
 121. Fantauzzi MF, Cass SP, McGrath JJC, Thayaparan D, Wang P, Stampfli MR, et al. Development and validation of a mouse model of contemporary cannabis smoke exposure. *ERJ Open Res*. 2021 Jul;7(3):00107–2021.
 122. Ribeiro LIG, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. *NPJ Prim care Respir Med*. 2016;26(August):16071.
 123. Kuate MPN, Ekeng BE, Kwizera R, Mandengue C, Bongomin F. Histoplasmosis overlapping with HIV and tuberculosis in sub-Saharan Africa: challenges and research priorities. *Ther Adv Infect Dis*. 2021;8.
 124. Agustí A, Vogelmeier C, Faner R. COPD 2020: changes and challenges. *Am J Physiol Lung Cell Mol Physiol*. 2020 Nov 1;319(5):L879–83.
 125. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. *Lancet*. 2022 Jun;399(10342):2227–42.
 126. Yang W, Li F, Li C, Meng J, Wang Y. Focus on early copd: Definition and

- early lung development. *Int J COPD*. 2021;16:3217–28.
127. Munir S, Takov V. Generalized Anxiety Disorder [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28722900>
128. Roumier A, Béchade C, Maroteaux L. Serotonin and the Immune System. In: *Serotonin*. Elsevier; 2019. p. 181–96.
129. Aleem MS, Sexton R, Akella J. Pneumonia In An Immunocompromised Patient [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32491775>
130. Carlesse F, Daudt LE, Seber A, Dutra AP, Melo AS de A, Simões B, et al. A consensus document for the clinical management of invasive fungal diseases in pediatric patients with hematologic cancer and/or undergoing hematopoietic stem cell transplantation in Brazilian medical centers. *Brazilian J Infect Dis*. 2019;23(6):395–409.
131. Dropulic LK, Lederman HM. Overview of Infections in the Immunocompromised Host. *Microbiol Spectr*. 2016;4(4):56–61.
132. Costumbrado J, Ghassemzadeh S. Spontaneous Pneumothorax [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29083723>
133. Lange SM, Parekh M. Collagen-Vascular Disease Associated With Interstitial Lung [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32644520>
134. Weissferdt A. Infectious Lung Disease. In: *Diagnostic Thoracic Pathology*. Cham: Springer International Publishing; 2020. p. 3–71.
135. Chang CY. Lung Abscess And Air-Fluid Level. *J Ayub Med Coll Abbottabad*. 2021;33(2):352–3.
136. Pahal P, Avula A, Sharma S. Emphysema [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29489292>

137. Salik I, Vashisht R, Abramowicz AE. Bronchopleural Fistula [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30521186>
138. Torres PPTES, Rabahi MF, Moreira MAC, Santana PRP, Gomes ACP, Marchiori E. Tomographic assessment of thoracic fungal diseases: a pattern and signs approach. *Radiol Bras*. 2018;51(5):313–21.
139. Majdawati A, Inayati. Diagnostic Test of Chest Radiograph on Fungal Pneumoniae. *Proc 4th Int Conf Sustain Innov 2020–Health Sci Nurs (ICoSIHSN 2020)*. 2021;33:228–33.
140. Wang J, Zhang C, Lin J, Zhang L, Li J, Yang F. Clinical diagnostic value of spiral CT in invasive pulmonary fungal infection. *Exp Ther Med*. 2019;4149–53.
141. Mank V, Brown K. Leukocytosis [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32809717>
142. Yao Z, Zhang Y, Wu H. Regulation of C-reactive protein conformation in inflammation. *Inflamm Res*. 2019 Oct;68(10):815–23.
143. Lapić I, Padoan A, Bozzato D, Plebani M. Erythrocyte Sedimentation Rate and C-Reactive Protein in Acute Inflammation. *Am J Clin Pathol*. 2020 Jan 1;153(1):14–29.
144. Nehring SM, Goyal A, Patel BC. C Reactive Protein [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28722873>
145. Brinkman JE, Sharma S. Respiratory Alkalosis [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29489286>
146. Brinkman JE, Sharma S. Physiology, Metabolic Alkalosis [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29493916>
147. Garrison DM, Pendela VS, Memon J. Cor Pulmonale [Internet]. StatPearls.

2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28613490>
148. Bhattacharya PT, Ellison MB. Right Ventricular Hypertrophy [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29763051>
149. Bao H, Cai H, Zhao Y, Huang X, Fan F, Zhang C, et al. Nonspecific ST-T changes associated with unsatisfactory blood pressure control among adults with hypertension in China: Evidence from the CSPTT study. *Medicine (Baltimore)*. 2017 Mar;96(13):e6423.
150. Antoniadis AP, Fragakis N. Intraventricular conduction disturbances: are we just looking at the tip of the iceberg? *Hellenic J Cardiol*. 2017;58(3):202–3.
151. Larssen MS, Steine K, Hilde JM, Skjørten I, Hodnesdal C, Liestøl K, et al. Mechanisms of ECG signs in chronic obstructive pulmonary disease. *Open Hear*. 2017 Mar 22;4(1):e000552.
152. Demissie WR, Tadessa S, Tegene E, Mariam TG. Changes on Electrocardiographic Patterns and Associated Factors among Chronic Obstructive Pulmonary Disease Patients. *Hear Res – Open J*. 2019;6(1):4–14.
153. Tural Onur S, Emet S, Sokucu SN, Onur I. T wave peak-to-end interval in COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2157–62.
154. Salman K, Priti S, Rana S. Evolution of ECG Abnormalities in Immune Dysfunction Exacerbation Patients with Chronic Obstructive Pulmonary Disease. *Acta Sci Microbiol*. 2020;3(4):195–201.
155. Pal A, Das A, Thakuria J. Electrocardiographic changes in chronic obstructive pulmonary disease - An observational study from North-East of India. *J Commun Dis*. 2020;52(1):32–7.
156. Alhamed Alduihi F. ECG Abnormalities in Patients with Acute

Exacerbation of Bronchiectasis and Factors Associated with High Probability of Abnormality. *Pulm Med.* 2021;2021:6649572.

157. Yamamoto H, Satomi K, Aizawa Y. Electrocardiographic manifestations in a large right-sided pneumothorax. *BMC Pulm Med.* 2021 Mar 23;21(1):101.
158. Gupta, Singla P, Goel N, Gupta A, Singh P, Gupta R. Screening for pulmonary mycosis: sputum versus bronchoalveolar lavage. *Egypt J Chest Dis Tuberc.* 2021;70(2):249.
159. Shen F, Sergi C. Sputum Analysis [Internet]. *StatPearls.* 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33085342>
160. Roden AC, Schuetz AN. Histopathology of fungal diseases of the lung. *Semin Diagn Pathol.* 2017 Nov;34(6):530–49.
161. Wang S, Lai J, Wu R, Zhang L, Huang M, Xiao Y, et al. Grocott Methenamine Silver Staining Is the Optimal Approach to Histological Diagnosis of Pulmonary Cryptococcosis. *Front Microbiol.* 2022;13(April):885511.
162. Kuate MPN, Nyasa R, Mandengue C, Tendongfor N, Bongomin F, Denning DW. Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. *J Microbiol Methods.* 2021;185(March):106226.
163. Oladele RO, Toriello C, Ogunsola FT, Ayanlowo OO, Foden P, Fayemiwo AS, et al. Prior subclinical histoplasmosis revealed in nigeria using histoplasmin skin testing. *PLoS One.* 2018;13(5):1–11.
164. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2007;45(7):807–25.

165. Azar MM, Hage CA. Clinical Perspectives in the Diagnosis and Management of Histoplasmosis. *Clin Chest Med*. 2017;38(3):403–15.
166. Nivoix Y, Ledoux MP, Herbrecht R. Antifungal Therapy: New and Evolving Therapies. *Semin Respir Crit Care Med*. 2020;41(1):158–74.
167. Noor A, Preuss C V. Amphotericin B [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29493952>
168. Li H, He J, Gu Y, Zhong N. Corticosteroid monotherapy in a case of bronchocentric granulomatosis with a two-year follow-up. *J Thorac Dis*. 2013 Oct;5(5):E207-9.
169. Fukahori S, Obase Y, Fukushima C, Takao D, Iriki J, Ozasa M, et al. Determining response to treatment for drug-induced bronchocentric granulomatosis by the forced oscillation technique. *Med*. 2021;57(12).
170. Kuzucuoglu M, Alpay Y, Aslan F, Aydin D. Diagnosis and Treatment of Bronchocentric Granulomatosis: A Rare Case Report. *Eur J Ther*. 2019;25(2):150–2.
171. Chang MR, Chopra N, Beenhouwer D, Goetz MB, Hoo GWS. Corticosteroids in the Management of Severe Coccidioidomycosis. *Am J Med*. 2019;132(1):110–3.
172. Williams DM. Clinical pharmacology of corticosteroids. *Respir Care*. 2018;63(6):655–70.
173. Firacative C. Invasive fungal disease in humans: Are we aware of the real impact? *Mem Inst Oswaldo Cruz*. 2020;115(9):1–9.
174. Badiie P, Hashemizadeh Z. Opportunistic invasive fungal infections: Diagnosis & clinical management. *Indian J Med Res*. 2014;139(FEB):195–204.
175. Rea G, Rudrappa M. Lobectomy [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31971762>

176. Kim HK. Video-Assisted Thoracic Surgery Lobectomy. *J Chest Surg*. 2021 Aug 5;54(4):239–45.
177. Gorton A, Lotfollahzadeh S. Segmental Lung Resection [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33620799>
178. Li H, Liu Y, Ling BC, Hu B. Efficacy of thoracoscopic anatomical segmentectomy for small pulmonary nodules. *World J Clin cases*. 2020 Jun 6;8(11):2227–34.
179. Chang B, Tucker WD, Burns B. Thoracotomy [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32491532>
180. Lederman D, Easwar J, Feldman J, Shapiro V. Anesthetic considerations for lung resection: preoperative assessment, intraoperative challenges and postoperative analgesia. *Ann Transl Med*. 2019 Aug;7(15):356.
181. Agarwal AK, Huda N. Interstitial Pulmonary Fibrosis [Internet]. StatPearls. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32491697>
182. Wheaton AK, Agarwal M, Jia S, Kim KK. Lung epithelial cell focal adhesion kinase signaling inhibits lung injury and fibrosis. *Am J Physiol - Lung Cell Mol Physiol*. 2017;312(5):L722–30.
183. Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. *Front Immunol*. 2020;11(September):1–3.
184. Chen IT, Huang LT, Chen CC, Chen CM. Molecular mechanisms underlying hyperoxia-induced lung fibrosis. *Pediatr Neonatol*. 2022;63(2):109–16.